Northeast Pharmaceutical Group Co Ltd (000597) — Cash Flow-to-Debt Ratio
Northeast Pharmaceutical Group Co Ltd (000597) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥274.09 Million could theoretically repay 0% of its total liabilities (CN¥8.05 Billion) in one year. Explore investment intensity of Northeast Pharmaceutical Group Co Ltd to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Northeast Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Northeast Pharmaceutical Group Co Ltd across 28 annual periods. Also explore Northeast Pharmaceutical Group Co Ltd (000597) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Northeast Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year debt coverage analysis for Northeast Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see market value of Northeast Pharmaceutical Group Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | CN¥1.11 Billion | CN¥7.22 Billion | ▲ +79.3% |
| 2024 | 0.09x | CN¥758.76 Million | CN¥8.88 Billion | ▲ +47.4% |
| 2023 | 0.06x | CN¥586.75 Million | CN¥10.11 Billion | ▼ -52.4% |
| 2022 | 0.12x | CN¥1.11 Billion | CN¥9.10 Billion | ▲ +45.1% |
| 2021 | 0.08x | CN¥746.51 Million | CN¥8.89 Billion | ▲ +18.3% |
| 2020 | 0.07x | CN¥570.92 Million | CN¥8.04 Billion | ▲ +73.6% |
| 2019 | 0.04x | CN¥352.60 Million | CN¥8.62 Billion | ▲ +16.6% |
| 2018 | 0.04x | CN¥285.09 Million | CN¥8.13 Billion | ▲ +193.7% |
| 2017 | -0.04x | CN¥-301.20 Million | CN¥8.05 Billion | ▼ -171.6% |
| 2016 | 0.05x | CN¥384.51 Million | CN¥7.36 Billion | ▲ +229.9% |
| 2015 | 0.02x | CN¥99.70 Million | CN¥6.29 Billion | ▲ +96.0% |
| 2014 | 0.01x | CN¥46.99 Million | CN¥5.81 Billion | ▲ +118.1% |
| 2013 | -0.04x | CN¥-266.38 Million | CN¥5.96 Billion | ▼ -320.4% |
| 2012 | 0.02x | CN¥86.09 Million | CN¥4.24 Billion | ▲ +135.9% |
| 2011 | -0.06x | CN¥-233.32 Million | CN¥4.13 Billion | ▼ -178.1% |
| 2010 | 0.07x | CN¥255.96 Million | CN¥3.54 Billion | ▼ -52.7% |
| 2009 | 0.15x | CN¥615.91 Million | CN¥4.03 Billion | ▼ -45.4% |
| 2008 | 0.28x | CN¥709.03 Million | CN¥2.53 Billion | ▲ +205.2% |
| 2007 | 0.09x | CN¥198.56 Million | CN¥2.16 Billion | ▲ +210.9% |
| 2006 | -0.08x | CN¥-106.00 Million | CN¥1.28 Billion | ▼ -203.9% |
| 2005 | 0.08x | CN¥111.40 Million | CN¥1.40 Billion | ▼ -41.5% |
| 2004 | 0.14x | CN¥211.06 Million | CN¥1.55 Billion | ▼ -2.3% |
| 2003 | 0.14x | CN¥230.08 Million | CN¥1.65 Billion | ▲ +60.0% |
| 2002 | 0.09x | CN¥157.41 Million | CN¥1.81 Billion | ▲ +106.8% |
| 2001 | 0.04x | CN¥78.84 Million | CN¥1.87 Billion | ▲ +105.6% |
| 2000 | 0.02x | CN¥36.13 Million | CN¥1.76 Billion | ▼ -35.1% |
| 1999 | 0.03x | CN¥54.62 Million | CN¥1.73 Billion | ▲ +760.8% |
| 1998 | 0.00x | CN¥-7.59 Million | CN¥1.59 Billion | — |